ArticleJournal of hematology & oncology2021

A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia.

Yunxin Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.